QQ客服 官方微博 反馈留言

浏览/检索结果: 共3条，第1-3条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Integration of Receptor Tyrosine Kinases Determines Sensitivity to PI3K alpha-selective Inhibitors in Breast Cancer 期刊论文 THERANOSTICS, 2017, 卷号: 7, 期号: 4, 页码: 974-986 作者:  Xu, Yi-chao;  Wang, Xiang;  Chen, Yi;  Chen, Si-meng;  Yang, Xin-ying 收藏  |  浏览/下载：14/0  |  提交时间：2019/01/08 BYL719  PI3K  ERK  receptor tyrosine kinase  breast cancer  predictive biomarker   The B-YOND study: A phase II three-arm randomized trial of the combination of tamoxifen plus goserelin acetate with BYL719 or buparlisib (BKM120) in premenopausal patients with hormone receptor-positive/HER2-negative locally advanced or metastatic breast 会议论文 作者:  Lu, Yen-Shen;  Park, Yeon Hee;  Shao, Zhimin;  Valenti, Roberta 收藏  |  浏览/下载：4/0  |  提交时间：2019/12/19 The B-YOND study: A phase II three-arm randomized trial of the combination of tamoxifen plus goserelin acetate with BYL719 or buparlisib (BKM120) in premenopausal patients with hormone receptor-positive/HER2-negative locally advanced or metastatic breast 期刊论文 Cancer Research, 2015, 卷号: 75 作者:  Lu Y.-S., Park Y.H., Shao Z., Valenti R. 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/19